Business Context and Reporting Period
This Form 8-K was filed by Histogenics Corporation (not Ocugen, Inc.) on March 24, 2017. The report addresses a regulatory event concerning the company's listing status on The NASDAQ Stock Market.
Key Financial Metrics
- Stockholders' Equity: $13.6 million (as reported in the Form 10-K for the fiscal year ended December 31, 2016).
- Market Value of Listed Securities (MVLS): Previously fell below the $50,000,000 threshold required by NASDAQ Listing Rule 5450(b)(2)(A).
- Revenue, Profit, Cash Flow, Debt: The filing text does not provide a clear value for these metrics.
Material Changes
The company previously received a notice on November 18, 2016, stating non-compliance with the minimum MVLS standard. On March 24, 2017, the company received confirmation from NASDAQ that it has regained compliance. This was achieved by meeting the alternative stockholders' equity standard under NASDAQ Listing Rule 5450(b)(1)(A), rather than the MVLS standard.
Outlook and Risks
NASDAQ has determined the compliance matter is closed. The company had a 180-day grace period ending May 17, 2017, to regain compliance, which it successfully met prior to the deadline. No specific forward-looking guidance or new risks were disclosed in this specific filing.
Investor Verification Points
- Verify the company name is Histogenics Corporation, not Ocugen, Inc.
- Confirm the $13.6 million stockholders' equity figure in the Form 10-K filed on March 16, 2017.
- Monitor future compliance with NASDAQ listing standards, specifically the MVLS requirement of $50,000,000.